IL156689A0 - Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof - Google Patents

Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Info

Publication number
IL156689A0
IL156689A0 IL15668901A IL15668901A IL156689A0 IL 156689 A0 IL156689 A0 IL 156689A0 IL 15668901 A IL15668901 A IL 15668901A IL 15668901 A IL15668901 A IL 15668901A IL 156689 A0 IL156689 A0 IL 156689A0
Authority
IL
Israel
Prior art keywords
epitopes
antibodies
isolated molecules
containing sulfated
sulfated moieties
Prior art date
Application number
IL15668901A
Other languages
English (en)
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of IL156689A0 publication Critical patent/IL156689A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15668901A 2000-12-29 2001-12-31 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof IL156689A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25894800P 2000-12-29 2000-12-29
US75118100A 2000-12-29 2000-12-29
PCT/US2001/049442 WO2002053700A2 (fr) 2000-12-29 2001-12-31 Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes

Publications (1)

Publication Number Publication Date
IL156689A0 true IL156689A0 (en) 2004-01-04

Family

ID=26946974

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15668901A IL156689A0 (en) 2000-12-29 2001-12-31 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Country Status (13)

Country Link
EP (1) EP1406930A4 (fr)
JP (1) JP2005503756A (fr)
KR (1) KR20030091953A (fr)
CN (1) CN100347194C (fr)
BR (1) BR0116764A (fr)
CA (1) CA2433225A1 (fr)
CZ (1) CZ20031982A3 (fr)
HU (1) HUP0700079A2 (fr)
IL (1) IL156689A0 (fr)
MX (1) MXPA03005945A (fr)
PL (1) PL366223A1 (fr)
RU (1) RU2003123101A (fr)
WO (1) WO2002053700A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
CN1678348A (zh) * 2002-07-01 2005-10-05 萨文特医药公司 用于治疗性治疗的组合物和方法
RU2006102571A (ru) * 2003-06-30 2007-08-20 Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) Специфические антитела человека
CA2536644A1 (fr) * 2003-06-30 2005-02-03 Bio-Technology General (Israel) Ltd. Anticorps et utilisations de ceux-ci
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
AR048840A1 (es) * 2004-05-11 2006-05-31 Boehringer Ingelheim Int Epitopes inductores de la muerte de las celulas t
ES2694239T3 (es) 2010-11-12 2018-12-19 Gentium S.R.L. Defibrótido para su uso en profilaxis y/o tratamiento de la enfermedad de Injerto contra huésped (GVHD)
CA2838952C (fr) 2011-06-13 2020-11-24 Stefan Bassarab Anticorps anti-psgl-1 et leurs utilisations
CA2874960C (fr) 2012-06-22 2021-05-18 Gentium S.P.A. Procede a base d'euglobuline pour la determination de l'activite biologique de defibrotide
WO2016013828A1 (fr) * 2014-07-21 2016-01-28 연세대학교 산학협력단 Mutant de domaine extracellulaire 1 de récepteur de chimiokines duffy sulfaté et utilisation associée
EP3026122A1 (fr) 2014-11-27 2016-06-01 Gentium S.p.A. Procédé à base cellulaire pour déterminer la puissance de défibrotide
JP2019031486A (ja) * 2017-08-04 2019-02-28 公立大学法人福島県立医科大学 新規ポリペプチド及びその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3326693A (en) * 1991-12-12 1993-07-19 Scripps Research Institute, The Bifunctional antithrombotic molecules and antithrombotic polypeptides
EP0833650A4 (fr) * 1995-06-14 2005-01-19 Gen Hospital Corp Ligands de p-selectine et procedes et molecules associes---
JPH11510543A (ja) * 1995-08-03 1999-09-14 ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ ペプチド及びセレクチン介在炎症のｏ−グリカン阻害剤
US5985833A (en) * 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
WO1999065712A2 (fr) * 1998-06-16 1999-12-23 The Board Of Regents Of The University Of Oklahoma Glycosulfopeptide, technique de synthese et utilisation

Also Published As

Publication number Publication date
CN1649900A (zh) 2005-08-03
CN100347194C (zh) 2007-11-07
EP1406930A4 (fr) 2007-01-10
EP1406930A2 (fr) 2004-04-14
WO2002053700A2 (fr) 2002-07-11
WO2002053700A3 (fr) 2004-02-12
JP2005503756A (ja) 2005-02-10
RU2003123101A (ru) 2005-03-10
PL366223A1 (en) 2005-01-24
KR20030091953A (ko) 2003-12-03
BR0116764A (pt) 2007-01-09
CZ20031982A3 (cs) 2004-09-15
CA2433225A1 (fr) 2002-07-11
MXPA03005945A (es) 2004-10-15
HUP0700079A2 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
MXPA03001590A (es) Anticuerpos para la il-1beta humana.
HUP0302376A3 (en) Anti-tnf antibodies, compositions, methods and uses
HUP0302128A3 (en) Anti-dual integrin antibodies, compositions, methods and uses
ZA200400521B (en) Antibodies to OPGL.
ZA200207589B (en) Multivalent antibodies and uses therefor. Multivalent antibodies and uses thereof.
AU3662101A (en) Cd40-binding apc-activating molecules
GB0029360D0 (en) Humanised antibodies and uses thereof
HUP0700079A2 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
GB0002093D0 (en) Antiperspirants
AU2002365894A8 (en) Antibodies to magmas and uses thereof
GB0030309D0 (en) Antibodies,Peptides,Analogs and uses thereof
MXPA03005511A (es) Toallitas antitranspirantes.
AU2002221132A1 (en) Novel antibody
GB0022670D0 (en) Molecules
GB0002625D0 (en) Dendroaspin molecules
GB0031284D0 (en) High affinity antibodies
GB0020568D0 (en) Novel antibody
AU8557801A (en) Modified proteins, isolated novel peptides, and uses thereof
AU2001236588A1 (en) Antibodies to the staphylococcal multidrug resistance (smr) protein
GB0003527D0 (en) Antibodies
GB0005071D0 (en) Antibodies
GB0019640D0 (en) Improvements to bottle
GB0005728D0 (en) Conserved antigens
GB0009538D0 (en) Antibody binding
GB0008160D0 (en) Monoclonal antibodies